Results 251 to 260 of about 11,127 (277)

Mepolizumab for the treatment of severe eosinophilic asthma

American Journal of Health-System Pharmacy, 2017
Published data on the pharmacology, pharmacokinetics and pharmacodynamics, and clinical efficacy and safety of the interleukin-5 antagonist mepolizumab are reviewed.Asthma of the eosinophilic phenotype is characterized by persistent eosinophilic airway inflammation promoted primarily by T-helper type 2 cytokines, the key regulator of eosinophils ...
Allen L. Wolford, Melissa F. Waineo, Shawna M. Cargill, Mara N. Poulakos   +3 more
openaire   +2 more sources

Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis

Drugs of Today, 2018
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare but potentially life-threatening antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis which affects, to varying degrees, the lungs, paranasal sinuses, heart, kidneys, skin and peripheral nervous system. It is strongly associated with asthma. Peripheral eosinophilia is a defining
Claire McBrien, Andrew Menzies-Gow
openaire   +3 more sources

Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis

New England Journal of Medicine
Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis characterized by eosinophilic inflammation. Benralizumab, a monoclonal antibody against the interleukin-5α receptor expressed on eosinophils, may be an option for treating EGPA.We conducted a multicenter, double-blind, phase 3, randomized, active-controlled noninferiority trial to ...
Wechsler, Michael E, Nair, Parameswaran, Terrier, Benjamin, Walz, Bastian, Bourdin, Arnaud, Jayne, David R W, Jackson, David J, Roufosse, Florence, Börjesson Sjö, Lena, Fan, Ying, Jison, Maria, McCrae, Christopher, Necander, Sofia, Shavit, Anat, Walton, Claire, Merkel, Peter A, MANDARA Study Group, Brussino, Luisa, Guida, Giuseppe   +18 more
openaire   +4 more sources

Hypereosinophilic Syndrome and Mepolizumab

New England Journal of Medicine, 2008
Robert M, Boucher, Lydia, Gilbert-McClain, Badrul, Chowdhury   +2 more
openaire   +4 more sources

From DREAM to REALITI‐A and beyond: Mepolizumab for the treatment of eosinophil‐driven diseases

Allergy: European Journal of Allergy and Clinical Immunology, 2022
Alberto Papi, Arnaud Bourdin, Florence Roufosse   +2 more
exaly  

Mepolizumab decreases tissue eosinophils while increasing type‐2 cytokines in eosinophilic chronic rhinosinusitis

Clinical and Experimental Allergy, 2022
Sophie Walter, Jacqueline Ho, Raquel Alvarado   +2 more
exaly  

Real‐world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta‐analysis

Clinical and Experimental Allergy, 2022
Dawei Luo, Ekaterina Khaleva, Graham Roberts   +2 more
exaly  

Mepolizumab for chronic rhinosinusitis with nasal polyps

The Lancet Respiratory Medicine, 2021
Philippe Gevaert, Guy Brusselle
openaire   +3 more sources

Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study

Arthritis and Rheumatology, 2022
Alessandra Bettiol, Maria Letizia Urban, Lorenzo Dagna   +2 more
exaly  

Real‐life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype

Clinical and Experimental Allergy, 2020
Santi Nolasco, Claudia Crimi, Corrado Pelaia   +2 more
exaly